Diabetes Mellitus, Type 2 Clinical Trial
Official title:
The Integration of Health Coaching and Diabetes Education in Type 2 Diabetes Mellitus Patients at Jakarta Primary Health Care: Role on Metabolic Control, Diabetes Complications, Inflammatory Marker, Behavior Changes, and Quality of Life
Verified date | April 2022 |
Source | Indonesia University |
Contact | Em Yunir, PhD |
Phone | +811161094 |
e.yunir[@]ui.ac.id | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Type 2 Diabetes Mellitus is a chronic disease with increasing incidence globally. It needs a comprehensive and continuous management approach that includes five pillars: education, nutritional management, physical activity, pharmacological treatment, and monitoring. To achieve good glycemic control, prevention of complications, and good quality of life as diabetes management goals, patients' capability to properly navigate diabetes management is a key. One evidence-based model to empower patients' self-management abilities is diabetes education and health coaching. Diabetes management at primary health care needs special concern since they play an important role in initial and continuing care for diabetes patients in the community. Therefore, the implementation of diabetes education and health coaching in primary health care is expected to improve the self-management abilities of people with diabetes
Status | Recruiting |
Enrollment | 200 |
Est. completion date | June 2023 |
Est. primary completion date | June 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Type 2 Diabetes Mellitus - >= 18 years old - Willing to follow the research by signing an informed consent Exclusion Criteria: - Patients with cognitive disease (such as dementia) - Patients with hearing or sight problem - Unable to live independently on daily basis |
Country | Name | City | State |
---|---|---|---|
Indonesia | University of Indonesia | Jakarta | DKI Jakarta |
Lead Sponsor | Collaborator |
---|---|
Indonesia University | Provincial Health Services Authority |
Indonesia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline HbA1C at 3 months and 6 months | HbA1C is indicator of glycemic control | Baseline, 3 and 6 months after intervention | |
Secondary | Change from baseline fasting plasma glucose at 3 and 6 months | Blood glucose monitoring | Baseline, 3 and 6 months after intervention | |
Secondary | Change from baseline serum lipid at 3 and 6 months | Lipid profile measurement includes total cholesterol, LDL-cholesterol, HDL-cholesterol, and triglycerides | Baseline, 3 and 6 months after intervention | |
Secondary | Change from baseline inflammatory marker at 3 and 6 months | Inflammatory marker used is hs-CRP (C-reactive protein) | Baseline, 3 and 6 months after intervention | |
Secondary | Change from baseline body mass index | Body mass index described by kg/m2 | Baseline, 3 and 6 months after intervention | |
Secondary | Change from baseline waist circumference | Waist circumference measured by cm | Baseline, 3 and 6 months after intervention | |
Secondary | Change from baseline body fat | Body fat measured by body impedance analysis | Baseline, 3 and 6 months after intervention | |
Secondary | Change from baseline left ventricular mass index | Left ventricular mass index measured using standard formula and corrected by body surface area | Baseline, 6 months after intervention | |
Secondary | Change from baseline left ventricular systolic function | Left ventricular systolic funciton was calculated from ejection fraction and global longitudinal strain (measured by echocardiography) | Baseline, 6 months after intervention | |
Secondary | Change from baseline left atrial volume | Left atrial volume was measured through biplane area calculation in echocardiography procedure | Baseline, 6 months after intervention | |
Secondary | Change from baseline right ventricular systolic function | Right ventricular systolic function was evaluated using TAPSE | Baseline, 6 months after intervention | |
Secondary | change from baseline left ventricular diastolic function | LV diastolic function was evaluated according to algorithm recommended by American Society of Echochardiography in 2016 | Baseline, 6 months after intervention | |
Secondary | Change from baseline electrocardiography pattern | Electrocardiography pattern was used to analyze cardiac rythm | Baseline and 6 months after intervention | |
Secondary | Change from baseline heart rate variability | Heart rate variability was measured using ECG Holter examination | Baseline and 6 months after intervention | |
Secondary | Baseline visual acuity | Visual acuity was measured by Peek acuity chart application using WHO classification | Baseline | |
Secondary | Baseline lens haziness | Lens haziness was evaluated using shadow test | Baseline | |
Secondary | Baseline retina examination | Retina was examined using funduscopic photography | Baseline | |
Secondary | Baseline intraocular pressure | Intraocular pressure was measured by cup-to-disc ratio using funduscopic photograpy | Baseline | |
Secondary | Change from baseline peripheral sensory neuropathy | Peripheral sensory neuropathy was measured using combination of subjective manifestation, 10 g Simme Weinstein monofilament and 128 Hz tuning fork | Baseline, 3 and 6 months after intervention | |
Secondary | Change from baseline peripheral autonomic neuropathy | Peripheral autonomic neuropathy was seen visually by objective examination (dry, scaly skin and cracked skin) | Baseline, 3 and 6 months after intervention | |
Secondary | Change from baseline peripheral motor neuropathy | Peripheral motor neuropathy was seen visually by objective examination (changes in the shape of fingers, muscle atrophy, or bone protrusions) | Baseline, 3 and 6 months after intervention | |
Secondary | Change from baseline peripheral arterial disease | Peripheral arterial disease was diagnosed through ankle brachial index measurement | Baseline, 3 and 6 months after intervention | |
Secondary | Change from baseline renal function | Renal function was measured by estimated glomerular filtration rate (eGFR) using creatinine data | Baseline and 6 months after intervention | |
Secondary | Change from baseline albuminuria | Albuminuria was measured by albumin creatinine ratio | Baseline and 6 months after intervention | |
Secondary | Change from baseline mean calorie intake | Evaluation of mean calorie intake using food record data | Baseline, 3 and 6 months after intervention | |
Secondary | Change from baseline global physical activity | Global physical activity was evaluated by global physical activity questionnaire | Baseline, 3 and 6 months after intervention | |
Secondary | Change from baseline medication adherence | Medication adherence was measured by Morisky Medication Adherence Scale (MMAS) | Baseline, 3 and 6 months | |
Secondary | Change from baseline quality of life | Quality of life was evaluated by EuroQol five-dimensional questionnaire. This questionnaire evaluates 5 dimensions of life. Each dimension scores 1-5 (1 means no problem and 5 means extreme problems). | Baseline, 3 and 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05666479 -
CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
|
||
Completed |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
Active, not recruiting |
NCT05661799 -
Persistence of Physical Activity in People With Type 2 Diabetes Over Time.
|
N/A | |
Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
Completed |
NCT02836704 -
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
|
Phase 4 | |
Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT04562714 -
Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy
|
N/A | |
Completed |
NCT02009488 -
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT05896319 -
Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2
|
N/A | |
Recruiting |
NCT05598203 -
Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes
|
N/A | |
Completed |
NCT05046873 -
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
|
Phase 1 | |
Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
Terminated |
NCT04090242 -
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
|
N/A | |
Completed |
NCT03620357 -
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
|
N/A | |
Completed |
NCT03604224 -
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
|
||
Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
Completed |
NCT03620890 -
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
|
Phase 4 | |
Withdrawn |
NCT05473286 -
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
|
||
Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
Completed |
NCT04531631 -
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes
|
Phase 2 |